Skip to main content
SpringerLink
Log in

Thiazides and Calcium Stones: Overrated or Underused?

  • Chapter
  • First Online:
Practical Controversies in Medical Management of Stone Disease

  • 641 Accesses

Abstract

The lifetime incidence of urolithiasis is approximately 10–15 % in the USA, with calcium-containing stones the most common offender. Among recurrent stone formers, thiazide-type diuretics have traditionally represented first-line therapy for prevention of recurrent calcium stones. However, with improved understanding of the benefits of lifestyle modification and alternative therapies for stone prevention, the utility of thiazides as first-line agents has recently come into question. This chapter will explore the rational for thiazide usage in the prevention of recurrent calcium stone disease, evaluate the evidence in favor of and against thiazides as first-line therapy, and finally examine the cost-effective use of thiazides and their comparative effectiveness to alternative forms of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-walsh urology. 10th ed. Philadelphia: Saunders Elsevier; 2012.

    Google Scholar 

  2. Pearle MS, Calhoun EA, Curhan GC. Urologic diseases in America project: urolithiasis. J Urol. 2005;173(3):848–57.

    Article  PubMed  Google Scholar 

  3. Brocks P, Dahl C, Wolf H, Transbøl I. Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet. 1981;2(8238):124–5.

    Article  CAS  PubMed  Google Scholar 

  4. Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol. 1982;128(5):903–7.

    CAS  PubMed  Google Scholar 

  5. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand. 1984;215(4):383–9.

    Article  CAS  PubMed  Google Scholar 

  6. Wilson D, Strauss A, Manuel M. Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urol Res. 1984;12:39–40.

    Google Scholar 

  7. Robertson WG, Peacock M, Selby PL, Williams RE, Clark P, Chisholm GD, et al. A multicentre trial to evaluate three treatments for recurrent idiopathic calcium stone disease—a preliminary report. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, editors. Urolithiasis and related clinical research. New York: Plenum Press; 1985.p. 545–8.

    Chapter  Google Scholar 

  8. Mortensen JT, Schultz A, Ostergaard AH. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. Int Urol Nephrol. 1986;18(3):265–9.

    Article  CAS  PubMed  Google Scholar 

  9. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol. 1988;139(4):679–84.

    CAS  PubMed  Google Scholar 

  10. Ohkawa M, Tokunaga S, Nakashima T, Orito M, Hisazumi H. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol. 1992;69(6):571–6.

    Article  CAS  PubMed  Google Scholar 

  11. Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol. 1993;22(6):78–86.

    Google Scholar 

  12. Fernández-Rodríguez A, Arrabal-Martín M, García-Ruiz MJ, Arrabal-Polo MA, Pichardo-Pichardo S, Zuluaga-Gómez A. Papel de las tiazidas en la profilaxis de la litiasis cálcica recidivante. Actas Urológicas Españolas. 2006;30:305–9.

    Article  PubMed  Google Scholar 

  13. Park S, Pearle MS. Pathophysiology and management of calcium stones. Urol Clin North Am. 2007;34(3):323–34.

    Article  PubMed  Google Scholar 

  14. Pak CY. Pharmacotherapy of kidney stones. Expert Opin Pharmacother. 2008;9(9):1509–18.

    Article  CAS  PubMed  Google Scholar 

  15. Lamberg BA, Kuhlback B. Effect of chlorothiazide and hydrochlorothiazide on the excretion of calcium in urine. Scand J Clin Lab Invest. 1959;11:351–7.

    Article  CAS  PubMed  Google Scholar 

  16. Huen SC, Goldfarb DS. Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. J Urol. 2007;177(4):1238–43.

    Article  CAS  PubMed  Google Scholar 

  17. Escribano J, Balaguer A, Pagone F, Feliu A, Roqué I, Figuls M. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004754.

    Google Scholar 

  18. Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol. 2010;5(10):1893–1903.

    Article  CAS  PubMed  Google Scholar 

  19. Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol. 1999;13(9):679–85.

    Article  CAS  PubMed  Google Scholar 

  20. Vigen R, Weideman R, Reilly R. Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol. 2011;43(3):813–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Asplin JR, Bauer KA, Kinder J, Müller G, Coe BJ, Parks JH, et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int. 2003;63(2):662–9.

    Article  CAS  PubMed  Google Scholar 

  22. Asplin JR, Donahue S, Kinder J, Coe FL. Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int. 2006;70(8):1463–7.

    Article  CAS  PubMed  Google Scholar 

  23. de Cogain M, Krambeck A. Pathogenesis of stone disease. AUA Update Series. 2011;30(Lesson 3):25–31.

    Google Scholar 

  24. Pak CY, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med. 1986;146(5):863–7.

    Article  CAS  PubMed  Google Scholar 

  25. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981–97.

    Article  Google Scholar 

  26. Eisner BH, Goldfarb DS, Pareek G. Pharmacologic treatment of kidney stone disease. Urol Clin North Am. 2013;40(1):21–30.

    Article  PubMed  Google Scholar 

  27. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742–8.

    Article  Google Scholar 

  28. Lotan Y, Pearle MS. Economics of stone management. Urol Clin North Am. 2007;34(3):443–53.

    Article  PubMed  Google Scholar 

  29. Lotan Y, Cadeddu JA, Roerhborn CG, Pak CY, Pearle MS. Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol. 2004;172(6 Pt 1):2275–81.

    Google Scholar 

  30. Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. European Urology. 2009;56(1):72–80.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Inter Med. 2013;158(7):535–43.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Mayo Clinic, 200 1st St., SW, Rochester, MN, 55905, USA

    John J. Knoedler & Amy E. Krambeck MD

Authors
  1. John J. Knoedler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy E. Krambeck MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy E. Krambeck MD .

Editor information

Editors and Affiliations

  1. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    Margaret S. Pearle

  2. Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

    Stephen Y. Nakada

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Knoedler, J., Krambeck, A. (2014). Thiazides and Calcium Stones: Overrated or Underused?. In: Pearle, M., Nakada, S. (eds) Practical Controversies in Medical Management of Stone Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9575-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9575-8_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-9574-1

  • Online ISBN: 978-1-4614-9575-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation